Comments for Hammer Stock Blog http://www.hammerstockblog.com Biotech stock reviews Thu, 21 Aug 2008 19:19:27 +0000 http://wordpress.org/?v=2.3.1 Comment on Rosetta Genomics - Mining Gold Out of Junk (Part I) by peter http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-290 peter Mon, 18 Aug 2008 19:41:20 +0000 http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-290 here's another one: Pacific Edge, LICR Publish Prognostic Gene Expression Profile for Melanoma [August 15, 2008] Welcome, Email this Story Printer-Friendly Version Ask the Editor RSS Feed In This Week's Issue Affymetrix Discusses Next-Gen Array Format, True Materials Buy, at Investor Conference In Its SNP-Genotyping Biz, Illumina Shifts Focus from Higher-Density Arrays to Content Microarray-Relevant NIH Grants in Fiscal Year 2008, July 2 — Aug. 2 Applied Precision, Microchips, University of California, Agilent Technologies Researchers Compare CNV Analysis Between Several Microarray Platforms Gentel Biosciences, Agnitio Science and Technology, Agilent Technologies, IMGM Laboratories, Bayer CropScience, Ariadne Genomics, Genomics, Illumina, Immucor, BioArray Solutions Ingenuity Systems Colin Collins, Derek Potter By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Researchers from the Melbourne, Australia, branch of the Ludwig Institute for Cancer Research and New Zealand firm Pacific Edge Biotechnology reported today that they have developed a gene expression-based test for melanoma progression. http://www.genomeweb.com/issues/news/148865-1.html does any of this change you take on Rosetta? here’s another one:
Pacific Edge, LICR Publish Prognostic Gene Expression Profile for Melanoma

[August 15, 2008]

Welcome,

Email this Story
Printer-Friendly Version
Ask the Editor
RSS Feed

In This Week’s Issue

Affymetrix Discusses Next-Gen Array Format, True Materials Buy, at Investor Conference
In Its SNP-Genotyping Biz, Illumina Shifts Focus from Higher-Density Arrays to Content

Microarray-Relevant NIH Grants in Fiscal Year 2008, July 2 — Aug. 2

Applied Precision, Microchips, University of California, Agilent Technologies

Researchers Compare CNV Analysis Between Several Microarray Platforms

Gentel Biosciences, Agnitio Science and Technology, Agilent Technologies, IMGM Laboratories, Bayer CropScience, Ariadne Genomics, Genomics, Illumina, Immucor, BioArray Solutions

Ingenuity Systems

Colin Collins, Derek Potter

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Researchers from the Melbourne, Australia, branch of the Ludwig Institute for Cancer Research and New Zealand firm Pacific Edge Biotechnology reported today that they have developed a gene expression-based test for melanoma progression.
http://www.genomeweb.com/issues/news/148865-1.html

does any of this change you take on Rosetta?

]]> Comment on Immunogen at ASCO 2008 by Ohad Hammer http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-287 Ohad Hammer Sun, 17 Aug 2008 21:53:29 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-287 Thanks Druggie. Good data from T-DM1 can certainly get IMGN higher, but in order to get to the 9-10$, they might need good IMGN901 data at ASH. Luckily, IMGN will have another shot on multiple myeloma with the Biotest ADC. I still didn't see anything exciting from the collaboration with Sanofi. AVE9633 is a flop and AVE1642 still hasn't produced positive data as well. Sanofi should publish data for SAR3419 at ASH, so this could be another catalyst. Thanks Druggie.
Good data from T-DM1 can certainly get IMGN higher, but in order to get to the 9-10$, they might need good IMGN901 data at ASH. Luckily, IMGN will have another shot on multiple myeloma with the Biotest ADC.

I still didn’t see anything exciting from the collaboration with Sanofi. AVE9633 is a flop and AVE1642 still hasn’t produced positive data as well. Sanofi should publish data for SAR3419 at ASH, so this could be another catalyst.

]]> Comment on Genentech’s Shiny New Platform by Ohad Hammer http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-286 Ohad Hammer Sun, 17 Aug 2008 21:36:20 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-286 None taken. This is exactly the point. The market is gradually embracing ADCs, which are going to be a must have in the industry. players that have validated and mature ADC technologies will become very valuable. The EXEL article will be published next weekend. None taken.
This is exactly the point. The market is gradually embracing ADCs, which are going to be a must have in the industry. players that have validated and mature ADC technologies will become very valuable.

The EXEL article will be published next weekend.

]]> Comment on Genentech’s Shiny New Platform by per99 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-284 per99 Fri, 15 Aug 2008 15:44:31 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-284 no offense, ohad, but I feel like you're putting too much weight on 2-3 companies that represent a tiny niche in biotech. You deserve the credit for identifying the potential of all these monoclonal abs companies, but there's a whole universe of companies out there. I really liked it when you started writing about areas other than antibodies (SNTA,PARD). What about EXEL, do you still intend to publish an article re the company? no offense, ohad, but I feel like you’re putting too much weight on 2-3 companies that represent a tiny niche in biotech. You deserve the credit for identifying the potential of all these monoclonal abs companies, but there’s a whole universe of companies out there.
I really liked it when you started writing about areas other than antibodies (SNTA,PARD). What about EXEL, do you still intend to publish an article re the company?

]]> Comment on Immunogen at ASCO 2008 by druggie http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-283 druggie Thu, 14 Aug 2008 14:47:01 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-283 your words were prophetic.. the eventual news of tras-dm1 going pivotal seems to be driving the stock price as we speak. we finally broke out of the 52 week highs.. next step is to break the intraday high of 6.24 in the spring 2007, then off to a real valuation in the high single digits.. Its time for imgn to put up or shut on 901. Its been in the clinic too long to not have hit MTD. It appears that combination trials are the future for this product, as there are too many drugs available to add a stand alone treatment at this time.. I would anticipate a combo trial with both revlimid and velcade possibly to begin in the fourth quarter. at some point in time, the drugs in the sanofy pipeline will need to be monetized into the share price. with 5 drugs already carrying imgn inside.. if sanofy drugs can begin to move into the clinic and into phase 2 trials, maybe wall street will fairly value imgn the stock... druggie your words were prophetic.. the eventual news of tras-dm1 going pivotal seems to be driving the stock price as we speak. we finally broke out of the 52 week highs.. next step is to break the intraday high of 6.24 in the spring 2007, then off to a real valuation in the high single digits..

Its time for imgn to put up or shut on 901. Its been in the clinic too long to not have hit MTD. It appears that combination trials are the future for this product, as there are too many drugs available to add a stand alone treatment at this time.. I would anticipate a combo trial with both revlimid and velcade possibly to begin in the fourth quarter.

at some point in time, the drugs in the sanofy pipeline will need to be monetized into the share price. with 5 drugs already carrying imgn inside.. if sanofy drugs can begin to move into the clinic and into phase 2 trials, maybe wall street will fairly value imgn the stock…

druggie

]]> Comment on Rosetta Genomics - Mining Gold Out of Junk (Part I) by Ohad Hammer http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-282 Ohad Hammer Sat, 09 Aug 2008 10:27:02 +0000 http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-282 Thanks for posting this, peter. I didn't know Pathwork already launched their product. We'll have to wait and see how ROSG's test will look like, but this is certainly a threat.ROSG's product will be based on fewer genes and will include more tumor types. Specificity should also be superior, but there is still no updated data. ohad Thanks for posting this, peter. I didn’t know Pathwork already launched their product. We’ll have to wait and see how ROSG’s test will look like, but this is certainly a threat.ROSG’s product will be based on fewer genes and will include more tumor types. Specificity should also be superior, but there is still no updated data.

ohad

]]> Comment on Genentech’s Shiny New Platform by Ohad Hammer http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-281 Ohad Hammer Sat, 09 Aug 2008 10:17:24 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-281 I wish I knew the answer to that. Don't forget that to date, Immunogen's technology generated the only ADC Genentech is developing, and sounds very happy with it. Theoretically, Immunogen's linkers and drugs can be used with the THIOMAB platform, so the potential is definitely there. Ohad I wish I knew the answer to that. Don’t forget that to date, Immunogen’s technology generated the only ADC Genentech is developing, and sounds very happy with it.
Theoretically, Immunogen’s linkers and drugs can be used with the THIOMAB platform, so the potential is definitely there.

Ohad

]]> Comment on Rosetta Genomics - Mining Gold Out of Junk (Part I) by peter http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-280 peter Thu, 07 Aug 2008 17:41:03 +0000 http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-i/#comment-280 did you know about Patchwork? http://209.85.141.104/search?q=cache:IfYN2m5P1oQJ:www.pathworkdx.com/collateral/PWDL_Technology_Backgrounder.pdf+Pathwork+rna&hl=en&ct=clnk&cd=3&gl=us did you know about Patchwork? http://209.85.141.104/search?q=cache:IfYN2m5P1oQJ:www.pathworkdx.com/collateral/PWDL_Technology_Backgrounder.pdf+Pathwork+rna&hl=en&ct=clnk&cd=3&gl=us

]]> Comment on Genentech’s Shiny New Platform by ihopeto http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-279 ihopeto Tue, 05 Aug 2008 22:08:21 +0000 http://www.hammerstockblog.com/genentech%e2%80%99s-new-shiny-platform/#comment-279 Hi Ohad I wonder what is the effect on of the new platform on IMGN's position within Genentech? Why did DNA decide to focus on SGEN's candidates especially after the success they've had with T-DM1? Thanks N.W Hi Ohad

I wonder what is the effect on of the new platform on IMGN’s position within Genentech? Why did DNA decide to focus on SGEN’s candidates especially after the success they’ve had with T-DM1?

Thanks
N.W

]]> Comment on Ikanos Communications – How Big is The VDSL Market -Part III (Europe) by amitan http://www.hammerstockblog.com/ikanos-communications-%e2%80%93-how-big-is-the-vsdl-market-part-iii-europe/#comment-278 amitan Tue, 05 Aug 2008 06:45:29 +0000 http://www.hammerstockblog.com/ikanos-communications-%e2%80%93-how-big-is-the-vsdl-market-part-iii-europe/#comment-278 Hi Ohad What is your current opinion on IKAN , and do you follow ORCT by the way ? What about Protalix (PLX)? Thanks. Hi Ohad
What is your current opinion on IKAN , and do you follow ORCT by the way ?

What about Protalix (PLX)?
Thanks.

]]> Comment on Micromet - Biting Cancer (Part II) by Ohad Hammer http://www.hammerstockblog.com/micromet-biting-cancer-part-ii/#comment-274 Ohad Hammer Sun, 27 Jul 2008 13:53:48 +0000 http://www.hammerstockblog.com/micromet-biting-cancer-part-ii/#comment-274 I still recommend holding it, as long as the BiTE platform keeps on producing such impressive results. The reason for the recent run is still unknown but it could have something to do with a large licensing deal in the making. For more clinical data we’ll have to wait until December. I still recommend holding it, as long as the BiTE platform keeps on producing such impressive results. The reason for the recent run is still unknown but it could have something to do with a large licensing deal in the making. For more clinical data we’ll have to wait until December.

]]> Comment on Immunogen at ASCO 2008 by Ohad Hammer http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-273 Ohad Hammer Sun, 27 Jul 2008 13:41:25 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-273 IMGN's share price will be determined by T-DM1's phase II results, to be presented at ASCO BC conference early September and IMGN901's phase I data at ASH in December. I believe that the T-DM1 data will be positive and will result in the advancement to a pivotal trial, so the stock has still room for growth until September. As to the IMGN901 data in December, we'll have to wait and see, I'm not falling for that again... ohad IMGN’s share price will be determined by T-DM1’s phase II results, to be presented at ASCO BC conference early September and IMGN901’s phase I data at ASH in December.
I believe that the T-DM1 data will be positive and will result in the advancement to a pivotal trial, so the stock has still room for growth until September.
As to the IMGN901 data in December, we’ll have to wait and see, I’m not falling for that again…

ohad

]]> Comment on Immunogen at ASCO 2008 by 4_reasons_unknown http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-272 4_reasons_unknown Fri, 25 Jul 2008 23:41:24 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-272 Ohad Thanks for taking the time, this piece is very informative. What are your near term expectations from IMGN. Do you see the 5$ level as a basis for further price increase? Ohad

Thanks for taking the time, this piece is very informative.
What are your near term expectations from IMGN. Do you see the 5$ level as a basis for further price increase?

]]> Comment on Micromet - Biting Cancer (Part II) by Steve http://www.hammerstockblog.com/micromet-biting-cancer-part-ii/#comment-271 Steve Wed, 23 Jul 2008 15:52:28 +0000 http://www.hammerstockblog.com/micromet-biting-cancer-part-ii/#comment-271 Ohad; thanks for familiarizing us with this great company! bought a nice chunk of MITI based on your analysis and am very happy at the moment, needless to say. Do you still recommend holding the stock even after the agressive move? Thanks Steve G. Ohad;

thanks for familiarizing us with this great company!
bought a nice chunk of MITI based on your analysis and am very happy at the moment, needless to say.
Do you still recommend holding the stock even after the agressive move?

Thanks
Steve G.

]]> Comment on Rosetta Genomics - Mining Gold Out of Junk (Part II) by Ohad Hammer http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-ii/#comment-268 Ohad Hammer Fri, 18 Jul 2008 11:45:08 +0000 http://www.hammerstockblog.com/rosetta-genomics-mining-gold-out-of-junk-part-ii/#comment-268 I don't think a lot of money will go to research institutions, but it remains ot be seen how much the different CLIA labs will get. I don’t think a lot of money will go to research institutions, but it remains ot be seen how much the different CLIA labs will get.

]]> Comment on Immunogen at ASCO 2008 by Ohad Hammer http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-267 Ohad Hammer Wed, 16 Jul 2008 20:27:21 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-267 Why wouldn't DNA run a phase III in Tykerb refractory patients? It would enable them to get T-DM1 in the market very early as you write. Although Tykerb user base is still limited, many physicians might use it off label before turning to Tykerb+xeloda. btw, if I were DNA, I would start a Xeloda+T-DM1 trial. Xeloda is Roche's drug so no problem here, there are no antganism issues like with Taxotere and most importantly, they may kick Tykerb out of Herceptin-resistant market. Sometimes the best defense is a good offense. Why wouldn’t DNA run a phase III in Tykerb refractory patients? It would enable them to get T-DM1 in the market very early as you write. Although Tykerb user base is still limited, many physicians might use it off label before turning to Tykerb+xeloda.

btw, if I were DNA, I would start a Xeloda+T-DM1 trial. Xeloda is Roche’s drug so no problem here, there are no antganism issues like with Taxotere and most importantly, they may kick Tykerb out of Herceptin-resistant market. Sometimes the best defense is a good offense.

]]> Comment on Immunogen at ASCO 2008 by druggie http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-266 druggie Wed, 16 Jul 2008 12:38:01 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-266 ohad.. what are your thoughts / experiences regarding the requirements on the phase 2.. for tras-dm1 ... must have prior tykerb/xeloda therapy. this very much sounds like dna may not run a phase 3 in this setting. do you know of any other drugs which have been approved in the phase setting under a situation like this. dna likely will only need 1 year to enroll this trial, and six months more of data maturation. equals xmas of 2009 , to apply for approval and likely approval by summer 2010.. druggie ohad..

what are your thoughts / experiences regarding the requirements on the phase 2.. for tras-dm1 … must have prior tykerb/xeloda therapy. this very much sounds like dna may not run a phase 3 in this setting.

do you know of any other drugs which have been approved in the phase setting under a situation like this. dna likely will only need 1 year to enroll this trial, and six months more of data maturation. equals xmas of 2009 , to apply for approval and likely approval by summer 2010..

druggie

]]> Comment on Immunogen at ASCO 2008 by Ohad Hammer http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-265 Ohad Hammer Tue, 15 Jul 2008 20:38:13 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-265 Thanks druggie. Judging by DNA's recent CC, they are seeing a very nice activity in the phase II. Thanks druggie.

Judging by DNA’s recent CC, they are seeing a very nice activity in the phase II.

]]> Comment on Immunogen at ASCO 2008 by druggie http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-264 druggie Mon, 14 Jul 2008 12:43:31 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-264 ohad.. thanks for your update... its my opinion that the tras-dm1 trial using tykerb/xeloda as a prerequisite of treatment will be the registrational trial everyone hopes for, whether announced as such or not. dna can make the trial pivotal based on the fact these patients have tried and failed the presumed LAST LINE OF DEFENSE, AND WONT have to repeat or run a control arm. the second trial tras-dm1 vs herc/taxotere will be a long running trial. but truly does have the makings of a heavyweight fight. with tras-dm1 the number one ranked contender and herc /taxotere the current standard. having seen the data ... i still believe tras-dm1 will blow this combo away.. with response rates of 80% in the very treatment experienced patient pop they ran the phase 2 trial. getting tras-dm1 into a naive treatment population should yield similar strong response rates/PR/CR .. regarding go /no go on a pivotal trial.. this decision was made a year ago when dna put into place multiple manufacturing suites in multiple locations around the world.. the rest is a poorly kept secret in my world. good luck with gary.. and his marketing theories. druggie ohad.. thanks for your update… its my opinion that the tras-dm1 trial using tykerb/xeloda as a prerequisite of treatment will be the registrational trial everyone hopes for, whether announced as such or not.

dna can make the trial pivotal based on the fact these patients have tried and failed the presumed LAST LINE OF DEFENSE, AND WONT have to repeat or run a control arm.

the second trial tras-dm1 vs herc/taxotere will be a long running trial. but truly does have the makings of a heavyweight fight. with tras-dm1 the number one ranked contender and herc /taxotere the current standard. having seen the data … i still believe tras-dm1 will blow this combo away.. with response rates of 80% in the very treatment experienced patient pop they ran the phase 2 trial. getting tras-dm1 into a naive treatment population
should yield similar strong response rates/PR/CR ..

regarding go /no go on a pivotal trial.. this decision was made a year ago when dna put into place multiple manufacturing suites in multiple locations around the world.. the rest is a poorly kept secret in my world.

good luck with gary.. and his marketing theories.

druggie

]]> Comment on Immunogen at ASCO 2008 by Ohad Hammer http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-263 Ohad Hammer Mon, 14 Jul 2008 05:14:15 +0000 http://www.hammerstockblog.com/immunogen-at-asco-2008/#comment-263 Gary Both trials will involve every three weeks adminsitration and can be turned into phase IIIs. I don't think it has anything to do with marketing because in late stage cancer dosing schedule is not regarded as a meaningful factor. It's all about the data. The go/no go decision should be made sooner rather than later, as DNA has plenty of PFS data to make a decision. Ohad Gary

Both trials will involve every three weeks adminsitration and can be turned into phase IIIs. I don’t think it has anything to do with marketing because in late stage cancer dosing schedule is not regarded as a meaningful factor. It’s all about the data.

The go/no go decision should be made sooner rather than later, as DNA has plenty of PFS data to make a decision.

Ohad

]]>